Stabilized hydrocodone pharmaceutical compositions with ethylenediaminetetraacetic acid

• US 20060205752A1
• Filed: 03/14/2005
• Published: 09/14/2006
• Est. Priority Date: 03/14/2005
• Status: Abandoned Application

• Current Assignee: Keith Whitehead
• Original Assignee: Keith Whitehead
• Inventors: Whitehead, Keith
• Application Number:
  US11/079,864
• Publication Number:
  US 20060205752A1
• Time in Patent Office: Days
• US Class Current: 514/282
• CPC Class Codes: A61K 2300/00 Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
• CPC Class Codes: A61K 31/195 having an amino group
• CPC Class Codes: A61K 31/485 Morphinan derivatives, e.g. morphine, codeine
• CPC Class Codes: A61K 47/183 Amino acids, e.g. glycine, EDTA or aspartame
• CPC Class Codes: A61K 9/0095 Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches A61K9/0007 takes precedence; eatable gels or foams A61K9/0056; oral mucosa adhesive forms A61K9/006

Abstract

Hydrocodone pharmaceutical formulations are stabilized with a stabilizing effective amount of ethylenediaminetetraacetic compound.

Claims

1. A stabilized hydrocodone pharmaceutical formulation, comprising:

a pharmaceutically effective amount of hydrocodone; and

,

a stabilizing effective amount of ethylenediaminetetraacetic acid for stabilizing the hydrocodone.

2. The formulation of claim 1, wherein the pharmaceutical formulation comprises an oral liquid composition.

3. The formulation of claim 2, wherein the oral liquid composition is selected from the group consisting of pharmaceutically acceptable emulsions, solutions, suspensions, syrups, elixirs and combinations thereof.

4. The formulation of claim 3, wherein the oral liquid composition comprises a solution.

5. The formulation of claim 1, wherein the hydrocodone is present in an amount of from about 2 mg to about 12 mg per 15 mL.

6. The formulation of claim 5, wherein the hydrocodone is present in an amount of from about 7.5 mg per 15 mL.

7. The formulation of claim 1, wherein the ethylenediaminetetraacetic acid comprises an ethylenediaminetetraacetic salt.

8. The formulation of claim 1, wherein the ethylenediaminetetraacetic acid is present an amount of from about 0.01% w/v to about 0.2% w/v.

9. The formulation of claim 8, wherein the ethylenediaminetetraacetic acid is present an amount of from about 0.03% w/v to about 0.1% w/v.

10. The formulation of claim 7, wherein the ethylenediaminetetraacetic salt is selected from the group consisting of di-potassium salt, di-sodium salt, calcium/di-sodium salt, sodium salt, tri-sodium salt, tetrasodium salt and combinations thereof.

11. The formulation of claim 1, further comprising a pharmaceutically effective amount of a second active agent.

12. The formulation of claim 11, wherein the second active agent includes acetaminophen.

13. The formulation of claim 12, wherein the acetaminophen is present in an amount of from about 125 mg to about 750 mg per 15 mL.

14. The formulation of claim 13, wherein the acetaminophen is present in an amount of about 500 mg per 15 mL.

15. A unit dosage of the formulation of claim 1, wherein the hydrocodone is present in an amount of about 7.5 mg, and the ethylenediaminetetraacefic acid is present in an amount of about 0.05 w/v, per 15 mL of solution.

16. A unit dosage of the formulation of claim 12, wherein the acetaminophen is present in an amount of about 500 mg, the hydrocodone is present in an amount of about 7.5 mg, and the ethylenediaminetetraacetic acid is present in an amount of about 0.05 w/v, per 15 mL of solution.

17. A method for stabilizing a hydrocodone formulation, comprising the steps of:

formulating a hydrocodone composition; and

,

adding to the formulated hydrocodone composition an effectively stabilizing amount of ethylenediaminetetraacetic acid.

18. The method of claim 17, further comprising the step of adding a second active agent to the hydrocodone composition.

19. The method of claim 18, wherein the second active agent comprises acetaminophen.

20. The method of claim 19, further comprising the step of formulating an oral liquid formulation.